Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

iGEMMdev

Financiado

Cerrado

Development and Characterisation of New Immunogenic GEMMs of Lung Cancer

Many studies have recently archived a remarkable clinical efficacy of immunotherapeutic treatments in several cancers including non-small cell lung cancer (NSCLC). However, these approaches are not always successful and it is curr... ver más

31/12/2018

The Francis Crick...

183K€

Presupuesto del proyecto: 183K€

Líder del proyecto

THE FRANCIS CRICK INSTITUTE LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-12-31

MSCA-IF-2015-EF: Marie Skłodowska-Curie Individual F...

I+D

Cerrada hace 9 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

The Francis Crick Institute

183.45K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ANTITUMOR IMMUNITY An in vivo RNAi approach to identify and evaluate suppressor... 187K€ Cerrado

SPACE Precision oncology of spatial immune escape mechanisms in ov... 2M€ Cerrado

Tumour T cells The fate and therapeutic potential of human neoantigen speci... 175K€ Cerrado

artFibro Artifying fibroblasts: Perturbation modelling in the lung tu... 2M€ Cerrado

MUTAEDITING Mutation driven immunoediting of human cancer? 2M€ Cerrado

CANCERNA RNA PROCESSING FOR ANTI-CANCER IMMUNOTHERAPY 6M€ Cerrado

Duración del proyecto: 33 meses Fecha Inicio: 2016-03-14
Fecha Fin: 2018-12-31

Líder del proyecto

THE FRANCIS CRICK INSTITUTE LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 183K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Many studies have recently archived a remarkable clinical efficacy of immunotherapeutic treatments in several cancers including non-small cell lung cancer (NSCLC). However, these approaches are not always successful and it is currently impossible to predict a therapeutic response or serious adverse event. These fundamental issues need to be addressed and, to recapitulate the complexity of interactions between immune cells and cancer, this has to be done in vivo. However, genetically engineered mouse models (GEMMs) of NSCLC do not mirror the genomic instability and the high mutations rate of their human counterparts. Consequently, these tumours rarely present neo-antigens that can induce an immune response, and are considered poorly immunogenic. To our knowledge, a genetically defined model of an immunogenic spontaneous tumour does not exist. Here, we propose to develop such an immunogenic GEMM (iGEMM). The leading mouse model of lung cancer is the GEMM Kraslsl-G12D/wtTrp53fl/fl (KP). We propose two strategies to induce either genomic instability or mutation rate in the KP model. 1) We will overexpress Mad2, a component of the mitotic spindle assembly checkpoint, to induce aneuploidy in KP tumours; 2) We will overexpress the cytidine deaminase Apobec3 to increase the mutation rate of KP tumours. The resulting immunogenic GEMMs (iGEMMs) will be characterised and used to assess new therapies that trigger an immune response and to address mechanisms which drive immunotolerance. iGEMMs will facilitate the investigation of currently available immunotherapies which will help predict clinical response to these therapies and investigation on alternative strategies to treat resistant lung tumours. All together, these investigations will provide novel information regarding the best strategies to cure NSCLC by modulation of the IS.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores